AMY LEMLY: Open Payments
NPI 1336605526 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,495 in 23 payments from 9 companies in 2025. Trend: 2023 $1,033 · 2024 $1,566 · 2025 $1,495
Food & beverage: $1,045Travel & lodging: $450
| Company | Payments | Amount |
|---|---|---|
| Edwards Lifesciences Corporation | 12 | $1,202 |
| AstraZeneca Pharmaceuticals LP | 2 | $141 |
| Novo Nordisk Inc | 2 | $31 |
| Novartis Pharmaceuticals Corporation | 2 | $29 |
| PFIZER INC. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: EVOQUE, FARXIGA, Wegovy, LEQVIO, VYNDAQEL, EVKEEZA, WAINUA, VERQUVO.
Industry payments across MS — which companies pay providers there.
